Pyxis Oncology, Inc. (NASDAQ:PYXS) Given Consensus Rating of “Moderate Buy” by Brokerages

Pyxis Oncology, Inc. (NASDAQ:PYXS) has been assigned a consensus rating of “Moderate Buy” from the nine brokerages that are presently covering the firm, Marketbeat reports. One research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $9.43.

PYXS has been the topic of a number of recent research reports. William Blair lowered Pyxis Oncology from an “outperform” rating to a “market perform” rating in a research report on Thursday, November 21st. Stephens initiated coverage on shares of Pyxis Oncology in a report on Friday, November 8th. They issued an “overweight” rating and a $13.00 price objective for the company. HC Wainwright reissued a “buy” rating and set a $5.00 target price (down from $7.00) on shares of Pyxis Oncology in a research note on Friday, December 20th. Finally, Royal Bank of Canada restated an “outperform” rating and set a $8.00 target price (down from $10.00) on shares of Pyxis Oncology in a research report on Friday, December 20th.

Pyxis Oncology Price Performance

Shares of PYXS opened at $1.76 on Tuesday. The company’s fifty day moving average price is $2.52 and its 200-day moving average price is $3.13. The firm has a market capitalization of $104.66 million, a PE ratio of -1.71 and a beta of 1.06. Pyxis Oncology has a 1-year low of $1.49 and a 1-year high of $6.85.

Insider Buying and Selling at Pyxis Oncology

In other Pyxis Oncology news, CFO Pamela Ann Connealy purchased 88,850 shares of the business’s stock in a transaction on Tuesday, November 26th. The shares were bought at an average cost of $1.96 per share, for a total transaction of $174,146.00. Following the completion of the purchase, the chief financial officer now directly owns 1,199,143 shares of the company’s stock, valued at approximately $2,350,320.28. This trade represents a 8.00 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 9.80% of the stock is currently owned by corporate insiders.

Institutional Trading of Pyxis Oncology

Several hedge funds have recently modified their holdings of PYXS. Millennium Management LLC lifted its stake in Pyxis Oncology by 125.3% in the second quarter. Millennium Management LLC now owns 1,336,908 shares of the company’s stock worth $4,425,000 after acquiring an additional 743,499 shares during the last quarter. Geode Capital Management LLC lifted its position in shares of Pyxis Oncology by 5.5% during the 3rd quarter. Geode Capital Management LLC now owns 1,084,727 shares of the company’s stock worth $3,982,000 after purchasing an additional 57,016 shares during the last quarter. Blue Owl Capital Holdings LP purchased a new position in Pyxis Oncology in the second quarter valued at approximately $3,462,000. State Street Corp lifted its holdings in shares of Pyxis Oncology by 28.0% in the 3rd quarter. State Street Corp now owns 951,251 shares of the company’s stock valued at $3,491,000 after purchasing an additional 208,344 shares during the last quarter. Finally, abrdn plc increased its holdings in shares of Pyxis Oncology by 28.9% in the 3rd quarter. abrdn plc now owns 913,045 shares of the company’s stock valued at $3,351,000 after acquiring an additional 204,742 shares during the period. 39.09% of the stock is currently owned by institutional investors and hedge funds.

Pyxis Oncology Company Profile

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.